Latest Industry Insights

The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.

Data integrity is fundamental to drug development and manufacturing but can be difficult to achieve for drug developers and manufacturers who have to navigate strict data integrity guidelines provided by regulatory authorities and find effective ways to attain compliance.

Cell and gene therapies first gained regulatory approval in 2017 by the US Food and Drug Administration (FDA). Several more therapies have since been developed, and there are now 18 approved to treat a variety of diseases Technology Networks recently had the pleasure of speaking with experts at Bio-Techne to learn more about the cell and gene therapy manufacturing process.

It’s imperative that scientists and leaders in the COVID-19 vaccine development space have good data management practices to ensure the quality of data and to recue the time-to-market now, and in the future. In this article, we explore how to make data work for you when manufacturing an effective vaccine.

Technology Networks spoke with Hugh H. Tansey, senior director of innovation and growth programs for laboratory equipment at Thermo Fisher Scientific to learn more about how the CTS Series Laboratory Equipment can deliver solutions for the key challenges in cell and gene therapy manufacturing.

See how cryo-EM advances are changing scientific research, particularly in cell and drug discovery studies, and the role that precision instruments are playing in this.

In drug discovery, time and monetary investments increase significantly the further candidates advance through the preclinical phase of testing, analysis and evaluation. By excluding non-viable compounds for safety and toxicity reasons early on, resources can be redirected to bring the most promising drugs to market sooner.

Biotech company COVAXX is developing a COVID-19 vaccine using a multi-antigen peptide platform, which not only targets the infamous SARS-CoV-2 Spike (S) protein but also targets other parts of the virus to enhance the immune response. Technology Networks spoke with Mei Mei Hu, co-founder of COVAXX, to learn more about the vaccine platform and the preclinical data that has been obtained for UB-612.

Infectious diseases remain a major health threat. The ongoing evolution of viral variants makes it likely that emerging infections will continue to occur – highlighting the need to develop new therapeutic and preventive approaches. Jeff Stein, PhD, President and CEO at Cidara Therapeutics tells Technology Networks more about a novel antiviral strategy they have developed called antiviral conjugates.

Technology Networks recently had the pleasure of speaking with Celyad Oncology’s CEO Filippo Petti. In this interview, Petti discusses key immunotherapy advances, highlights the two main CAR T-cell therapy approaches and elaborates on the company’s “off-the-shelf” CAR T cells.